OBJECTIVE: To examine the effect of rimonabant on neurocognitive impairments in people with schizophrenia. METHODS: Participants entered a 16-week double-blind, placebo-controlled, randomized clinical trial. A neurocognitive battery was administered at baseline and end of study. RESULTS: In comparison to rimonabant (20mg/day), placebo-treated participants exhibited a significant improvement on the Repeatable Battery for the Assessment of Neuropsychological Status total score. In contrast, rimonabant was associated with significant improvement on a probabilistic learning task. There were no other significant treatment effects. CONCLUSIONS:Rimonabant did not improve global cognitive functioning, but did improve a specific learning deficit based on response to positive feedback.
RCT Entities:
OBJECTIVE: To examine the effect of rimonabant on neurocognitive impairments in people with schizophrenia. METHODS:Participants entered a 16-week double-blind, placebo-controlled, randomized clinical trial. A neurocognitive battery was administered at baseline and end of study. RESULTS: In comparison to rimonabant (20mg/day), placebo-treated participants exhibited a significant improvement on the Repeatable Battery for the Assessment of Neuropsychological Status total score. In contrast, rimonabant was associated with significant improvement on a probabilistic learning task. There were no other significant treatment effects. CONCLUSIONS:Rimonabant did not improve global cognitive functioning, but did improve a specific learning deficit based on response to positive feedback.
Authors: Christopher M Wilk; James M Gold; John J Bartko; Faith Dickerson; Wayne S Fenton; Michael Knable; Christopher Randolph; Robert W Buchanan Journal: Am J Psychiatry Date: 2002-05 Impact factor: 18.112
Authors: Peter J McLaughlin; Julia E Jagielo-Miller; Emily S Plyler; Kerry K Schutte; V Kiran Vemuri; Alexandros Makriyannis Journal: Psychopharmacology (Berl) Date: 2017-02-01 Impact factor: 4.530
Authors: Philip G Tibbo; Kyle A McKee; Jeffrey H Meyer; Candice E Crocker; Katherine J Aitchison; Raymond W Lam; David N Crockford Journal: Can J Psychiatry Date: 2020-09-11 Impact factor: 4.356
Authors: Maju Mathew Koola; David A Gorelick; Robert P McMahon; Fang Liu; Marilyn A Huestis; Jared Linthicum; Stephanie M Feldman; Kimberly R Warren; Heidi J Wehring; Deanna L Kelly Journal: Schizophr Res Date: 2013-12-12 Impact factor: 4.939
Authors: Miquel Bioque; Borja García-Bueno; Karina S Macdowell; Ana Meseguer; Pilar A Saiz; Mara Parellada; Ana Gonzalez-Pinto; Roberto Rodriguez-Jimenez; Antonio Lobo; Juan C Leza; Miguel Bernardo Journal: Neuropsychopharmacology Date: 2013-07-04 Impact factor: 7.853
Authors: Adriana M Marques; Michele V Macena; Aline R Cardoso; Camila S O Hammes; Fernanda M L Pinheiro; Newton G Castro; Gilda A Neves Journal: Psychopharmacology (Berl) Date: 2020-02-24 Impact factor: 4.530
Authors: Dennis J Sholler; Marilyn A Huestis; Benjamin Amendolara; Ryan Vandrey; Ziva D Cooper Journal: Pharmacol Biochem Behav Date: 2020-10-18 Impact factor: 3.533